CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)
Globe Newswire•27/08/2026•08:00 ET
0
Whiz Insights
- Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC -
- Potential Varseta-M monotherapy registrational study in R/R mCRC planned for initiation in 1H 2027 -
Get started
Create a free account to read the full story.